ResMed's (RMD) FY26 result is a case study in how much forward guidance matters this reporting season. The sleep device manufacturer delivered a solid set of FY26 numbers: revenue in line with forecasts, a slight earnings beat and a 10% dividend increase.But analysts had made clear ahead of the res…
Q4 and FY 2026 saw strong revenue and EPS growth, with robust free cash flow and increased capital returns. FY 2027 guidance anticipates 5%-7% core revenue growth, 12%-14% core EPS growth, and significant shareholder returns, despite Astral-related headwinds.Based on ResMed Inc. [RMD] Q4 2026 Audio…
Medical device company ResMed NYSE:RMDwill be announcing earnings results this Thursday after the bell. Here’s what to expect.ResMed beat analysts’ revenue expectations last quarter, reporting revenues of $1.43 billion, up 10.8% year on year. It was a satisfactory quarter for the company, with a be…
For a sector many self-funded retirees and growth investors alike have long treated as one of the sturdiest anchors in an ASX portfolio, FY26 delivered a gut punch. Healthcare was the ASX's second-worst performing sector, down over 36% for the year – but for some household names like CSL (CSL), Coc…
Resmed RMD has entered into a definitive agreement to sell its MatrixCare business to private equity firm Frazier Healthcare Partners. The divestiture aligns with the company's long-term strategy to sharpen its focus on higher-growth opportunities across sleep health, breathing health and connected…
Sharpens Resmed’s focus on high-growth sleep and connected care marketsSAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- Resmed NYSE:RMD, ASX:RMD, the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has entered into a definitive agreement…
ResMed Inc. (NYSE:RMD) will report fiscal Q4 2026 results Aug. 6 after the close and host an investor webcast, even as Morgan Stanley downgraded the stock and trimmed its target, citing margin pressures, a muted outlook, Philips competition in U.S. PAP devices and GLP-1 demand risk.Previous Week Re…
